We think a “barbell approach” combining both sectors and ETFs may be beneficial to balance risk and capture opportunities as AI advances drug development and productivity.
Chief Investment Officer Scott Ladner believes in focusing on biotech and large pharmaceutical companies for AI-driven healthcare investments.
Not investment advice; mentions of specific securities are illustrative in nature.
